Search
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.
Ularitide
go.drugbank.com/drugs/DB05034InvestigationalUrodilatin is produced in the kidney and excreted into the urine, and thus exists in low levels naturally in the systemic blood circulation. … When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation.
NE-180
go.drugbank.com/drugs/DB05619ExperimentalNE-180 was under investigation in a clinical trial conducted in the European Union.
Hydroxyethyl ethylcellulose
go.drugbank.com/drugs/DB14139ApprovedHydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.
Betulinic Acid
go.drugbank.com/drugs/DB12480ApprovedWithdrawnBetulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.
1,4-Dithiothreitol
go.drugbank.com/drugs/DB04447ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Neuropeptide Y
go.drugbank.com/drugs/DB11788ApprovedInvestigationalWithdrawnNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Digoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedDigoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalIt is used to treat Macular degeneration. … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.